Difference between revisions of "Azevedo R, et al. Clin. Proteom. (2018) cited as Ref 666 in DOI: 10.1038/s41392-020-0110-5 (Q9929)"
Jump to navigation
Jump to search
(Created claim: Volume (P103): 15, #quickstatements; #temporary_batch_1590009084631) |
(Created claim: Page(s) (P105): 22-, #quickstatements; #temporary_batch_1590074839150) |
||
| (One intermediate revision by the same user not shown) | |||
| Property / title | |||
| + | CD44 glycoprotein in cancer: a molecular conundrum hampering clinical applications (English) | ||
| Property / title: CD44 glycoprotein in cancer: a molecular conundrum hampering clinical applications (English) / rank | |||
| + | Normal rank | ||
| Property / Page(s) | |||
| + | 22- | ||
| Property / Page(s): 22- / rank | |||
| + | Normal rank | ||
Latest revision as of 15:48, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Azevedo R, et al. Clin. Proteom. (2018) cited as Ref 666 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Azevedo R
0 references
2018
0 references
Clin. Proteom.
0 references
15
0 references
CD44 glycoprotein in cancer: a molecular conundrum hampering clinical applications (English)
0 references
22-
0 references
